Irati
Garmendia Iturbe
Researcher to 2019
Instituto de Salud Carlos III
Madrid, EspañaPublications in collaboration with researchers from Instituto de Salud Carlos III (2)
2021
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3